Abstract
Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the gynecologic malignancies. Treatments have comprised the use of immunotherapeutic agents as well as oncolytic viruses, with varying results for reasons that remain to be clarified. To better understand the mechanisms that may help predict treatment outcome, we have evaluated innate immune signaling in select ovarian cancer cell lines, governed by the Stimulator of Interferon Genes (STING), which controls self or viral DNA-triggered cytokine production. Our results indicate that STING-dependent signaling is habitually defective in majority of ovarian cancer cells examined, frequently through the suppression of STING and/or the cyclic dinucleotide (CDN) enzyme Cyclic GMP-AMP synthase (cGAS) expression, by epigenetic processes. However, STINGindependent, dsRNA-activated innate immune cytokine production, which require RIG-I/MDA5, were largely unaffected. Such defects enabled ovarian cancer cells to avoid DNA damage-mediated cytokine production, which would alert the immunosurveillance system. Loss of STING signaling also rendered ovarian cancer cells highly susceptible to viral oncolytic g34.5 deleted-HSV1 (Herpes simplex virus) infection in vitro and in vivo. Implications: STING signaling evaluation in tumors may help predict disease outcome and possibly dictate the efficacy of oncoviral and other types of cancer therapies.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 974-986 |
| Number of pages | 13 |
| Journal | Molecular Cancer Research |
| Volume | 17 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 2019 |
Fingerprint
ASJC Scopus subject areas
- Molecular Biology
- Oncology
- Cancer Research
Cite this
Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis. / De Queiroz, Nina Marí Gual Pimenta; Xia, Tianli; Konno, Hiroyasu; Barber, Glen N.
In: Molecular Cancer Research, Vol. 17, No. 4, 01.01.2019, p. 974-986.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis
AU - De Queiroz, Nina Marí Gual Pimenta
AU - Xia, Tianli
AU - Konno, Hiroyasu
AU - Barber, Glen N
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the gynecologic malignancies. Treatments have comprised the use of immunotherapeutic agents as well as oncolytic viruses, with varying results for reasons that remain to be clarified. To better understand the mechanisms that may help predict treatment outcome, we have evaluated innate immune signaling in select ovarian cancer cell lines, governed by the Stimulator of Interferon Genes (STING), which controls self or viral DNA-triggered cytokine production. Our results indicate that STING-dependent signaling is habitually defective in majority of ovarian cancer cells examined, frequently through the suppression of STING and/or the cyclic dinucleotide (CDN) enzyme Cyclic GMP-AMP synthase (cGAS) expression, by epigenetic processes. However, STINGindependent, dsRNA-activated innate immune cytokine production, which require RIG-I/MDA5, were largely unaffected. Such defects enabled ovarian cancer cells to avoid DNA damage-mediated cytokine production, which would alert the immunosurveillance system. Loss of STING signaling also rendered ovarian cancer cells highly susceptible to viral oncolytic g34.5 deleted-HSV1 (Herpes simplex virus) infection in vitro and in vivo. Implications: STING signaling evaluation in tumors may help predict disease outcome and possibly dictate the efficacy of oncoviral and other types of cancer therapies.
AB - Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the gynecologic malignancies. Treatments have comprised the use of immunotherapeutic agents as well as oncolytic viruses, with varying results for reasons that remain to be clarified. To better understand the mechanisms that may help predict treatment outcome, we have evaluated innate immune signaling in select ovarian cancer cell lines, governed by the Stimulator of Interferon Genes (STING), which controls self or viral DNA-triggered cytokine production. Our results indicate that STING-dependent signaling is habitually defective in majority of ovarian cancer cells examined, frequently through the suppression of STING and/or the cyclic dinucleotide (CDN) enzyme Cyclic GMP-AMP synthase (cGAS) expression, by epigenetic processes. However, STINGindependent, dsRNA-activated innate immune cytokine production, which require RIG-I/MDA5, were largely unaffected. Such defects enabled ovarian cancer cells to avoid DNA damage-mediated cytokine production, which would alert the immunosurveillance system. Loss of STING signaling also rendered ovarian cancer cells highly susceptible to viral oncolytic g34.5 deleted-HSV1 (Herpes simplex virus) infection in vitro and in vivo. Implications: STING signaling evaluation in tumors may help predict disease outcome and possibly dictate the efficacy of oncoviral and other types of cancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=85063756562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063756562&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-18-0504
DO - 10.1158/1541-7786.MCR-18-0504
M3 - Article
C2 - 30587523
AN - SCOPUS:85063756562
VL - 17
SP - 974
EP - 986
JO - Molecular Cancer Research
JF - Molecular Cancer Research
SN - 1541-7786
IS - 4
ER -